| Business Summary | | AtheroGenics,
Inc.
is
a
pharmaceutical
company
focused
on
the
discovery,
development
and
commercialization
of
novel
drugs
for
the
treatment
of
chronic
inflammatory
diseases,
such
as
atherosclerosis,
rheumatoid
arthritis
and
asthma.
The
Company
designed
its
lead
product
candidate,
AGI-1067,
to
benefit
patients
with
coronary
artery
disease,
which
is
atherosclerosis
of
the
blood
vessels
of
the
heart.
The
Company
has
developed
a
proprietary
vascular-protectant
(v-protectant)
technology
platform
to
discover
drugs
for
the
treatment
of
chronic
inflammation.
AGI-1067
is
the
Company's
v-protectant
candidate
that
is
most
advanced
in
clinical
development.
The
Company
has
identified
other
potential
v-protectant
product
candidates
to
treat
asthma,
exacerbation
of
rheumatologic
diseases
and
solid
organ
transplant
rejection.
The
Company
is
evaluating
these
v-protectant
product
candidates
to
choose
lead
product
candidates
for
clinical
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AtheroGenics
is
a
pharmaceutical
company
focused
on
discovery,
development
and
commercialization
of
novel
drugs
for
the
treatment
of
chronic
inflammatory
diseases.
For
the
six
months
ended
6/30/01,
revenues
fell
54%
to
$1.9
million.
Net
loss
increased
9%
to
$7.1
million.
Revenues
reflect
lower
billings
to
the
Phase
II
clinical
study.
Higher
net
loss
reflects
increased
research
and
development
expenses
associated
with
AGIX-4207
clinical
trials
and
other
pre-clinical
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Henos, 52 Chairman | -- | -- | Russell Medford, M.D., Ph.D., 46 Pres,
CEO, Director | $392K | -- | Mark Colonnese, 46 CFO,
VP of Fin. and Admin., Assistant Sec. | 270K | $342K | Mitchell Glass, M.D., 49 Sr.
VP, Strategic Drug Devel. | 258K | 398K | William Scott, Ph.D., 60 VP,
Director | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|